University of Leicester
Browse
BJS11214_edited_HG5_AS5_26.05.2019.pdf (377.24 kB)

Observational study of the medical management of patients with peripheral artery disease

Download (377.24 kB)
Version 2 2020-04-06, 15:56
Version 1 2020-04-06, 15:55
journal contribution
posted on 2020-04-06, 15:56 authored by A Saratzis, NEM Jaspers, B Gwilym, O Thomas, A Tsui, R Lefroy, M Parks, V Htun, Z Mera, A Thatcher, D Bosanquet, R Forsythe, R Benson, N Dattani, G Dovell, T Lane, J Shalhoub, D Sidloff, FLJ Visseren, JAN Dorresteijn, T Richards
Background: Previous research has suggested that patients with peripheral artery disease (PAD) are not offered adequate risk factor modification, despite their high cardiovascular risk. The aim of this study was to assess the cardiovascular profiles of patients with PAD and quantify the survival benefits of target-based risk factor modification. Methods: The Vascular and Endovascular Research Network (VERN) prospectively collected cardiovascular profiles of patients with PAD from ten UK vascular centres (April to June 2018) to assess practice against UK and European goal-directed best medical therapy guidelines. Risk and benefits of risk factor control were estimated using the SMART-REACH model, a validated cardiovascular prediction tool for patients with PAD. Results: Some 440 patients (mean(s.d.) age 70(11) years, 24·8 per cent women) were included in the study. Mean(s.d.) cholesterol (4·3(1·2) mmol/l) and LDL-cholesterol (2·7(1·1) mmol/l) levels were above recommended targets; 319 patients (72·5 per cent) were hypertensive and 343 (78·0 per cent) were active smokers. Only 11·1 per cent of patients were prescribed high-dose statin therapy and 39·1 per cent an antithrombotic agent. The median calculated risk of a major cardiovascular event over 10 years was 53 (i.q.r. 44–62) per cent. Controlling all modifiable cardiovascular risk factors based on UK and European guidance targets (LDL-cholesterol less than 2 mmol/l, systolic BP under 140 mmHg, smoking cessation, antiplatelet therapy) would lead to an absolute risk reduction of the median 10-year cardiovascular risk by 29 (20–38) per cent with 6·3 (4·0–9·3) cardiovascular disease-free years gained. Conclusion: The medical management of patients with PAD in this secondary care cohort was suboptimal. Controlling modifiable risk factors to guideline-based targets would confer significant patient benefit.

Funding

This research was funded partly by Amgen. None of the investigators received reimbursements or financial incentives.

History

Citation

Saratzis, A., Jaspers, N.E.M., Gwilym, B., Thomas, O., Tsui, A., Lefroy, R., Parks, M., Htun, V., Mera, Z., Thatcher, A., Bosanquet, D., Forsythe, R., Benson, R., Dattani, N., Dovell, G., Lane, T., Shalhoub, J., Sidloff, D., Visseren, F.L.J., Dorresteijn, J.A.N., Richards, T. and (2019), Observational study of the medical management of patients with peripheral artery disease. Br J Surg, 106: 1168-1177. doi:10.1002/bjs.11214

Version

  • VoR (Version of Record)

Published in

BRITISH JOURNAL OF SURGERY

Volume

106

Issue

9

Pagination

1168 - 1177 (10)

Publisher

WILEY

issn

0007-1323

eissn

1365-2168

Acceptance date

2019-03-23

Copyright date

2020

Available date

2019-07-01

Publisher version

https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.11214?

Spatial coverage

England

Language

English

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC